IC Value
About Us
Editorial Board
Contact Us

The effect of pioglitazone, a ppar-γ agonist, on cardiovascular risk factors in type 2 diabetics

Authors:Navjot Kaur, Satinder Kaur, Parminder Singh, Prerna Goyal, Indu Verma
Int J Biol Med Res. 2012; 3(2): 1558 – 1560  |  PDF File


Pioglitazone, a thiazolidinedione (TZD) has an insulin sensitizing action, is being used for long term glycemic control. In addition it has been shown to be having favorable effect on cardiovascular risk factors. To study these effect of TZD, 50 patients of Type 2 Diabetes visiting OPD/IPD of DMC&H, Ludhiana were treated with pioglitazone (15-45 mg/d ) for 16 weeks. Biochemical markers of glycemic control ( FBS, insulin levels, HbA1c ) and cardiovascular risk factors ( lipid profile, CRP, fibrinogen ) were analyzed at 0 and 16 weeks of treatment. There was significant decrease in FBS, HbA1c and insulin levels after the treatment showing good glycemic control. There was significant decrease in triglyceride levels,10% increase in HDL levels and 55% decrease in CRP levels showing anti-inflammatory and antiatherogenic effect of pioglitazone. But no significant change could be observed in total cholestrol, LDL and fibrinogen levels. These properties seem to make the drug particularly useful in patients with insulin resistant type 2 diabetes.